Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.252,68
-1,03%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Eyetech Pharmaceuticals (MM) (EYET) Eyetech Pharmaceuticals (MM) (EYET) Notizie

EYET

Eyetech (EYET)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EYET
DataOraFonteTitoloSimboloCompagnia
12/11/200523:52Business WireOSI Pharmaceuticals and Eyetech Pharmaceuticals Confirm November 14th ClosingNASDAQ:EYETEyetech Pharmaceuticals (MM)
10/11/200517:30PR Newswire (US)Eyetech Provides Update on Status of Pending Acquisition by OSI PharmaceuticalsNASDAQ:EYETEyetech Pharmaceuticals (MM)
31/10/200523:00PR Newswire (US)Eyetech Reports Third Quarter 2005 Financial ResultsNASDAQ:EYETEyetech Pharmaceuticals (MM)
17/10/200515:30PR Newswire (US)Eyetech Announces Enrollment of the First Patient in a Phase 3 Clinical Trial of Macugen(R) (pegaptanib sodium injection) in DiaNASDAQ:EYETEyetech Pharmaceuticals (MM)
05/10/200515:30PR Newswire (US)Recent Analyses Suggest That Treatment With Macugen(R) (pegaptanib sodium injection) May Provide Better Results for Patients WitNASDAQ:EYETEyetech Pharmaceuticals (MM)
16/09/200515:15PR Newswire (US)Macugen(R) (pegaptanib sodium injection) Receives Positive Opinion for Treatment of Neovascular Age-Related Macular DegenerationNASDAQ:EYETEyetech Pharmaceuticals (MM)
22/08/200502:48PR Newswire (US)OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger AgreementNASDAQ:EYET
22/08/200501:45Business WireOSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement; Acquisition Projected to be AccNASDAQ:EYETEyetech Pharmaceuticals (MM)
09/08/200515:30PR Newswire (US)Macugen(R) (pegaptanib sodium injection) Named Innovative Pharmaceutical Product Of The Year At The 2005 Pharmaceutical AchievemNASDAQ:EYETEyetech Pharmaceuticals (MM)
27/07/200523:30PR Newswire (US)Eyetech Reports Second Quarter 2005 Financial ResultsNASDAQ:EYETEyetech Pharmaceuticals (MM)
18/07/200520:30PR Newswire (US)Eyetech and Pfizer Comment on Data Presented at Meeting of Retinal SpecialistsNASDAQ:EYET
15/07/200519:30PR Newswire (US)Eyetech To Announce Second Quarter 2005 Financial Results On July 27, 2005NASDAQ:EYETEyetech Pharmaceuticals (MM)
22/06/200514:30PR Newswire (US)Eyetech Raises Full-Year Sales Forecast for Macugen(R) (pegaptanib sodium injection)NASDAQ:EYETEyetech Pharmaceuticals (MM)
21/06/200521:33PR Newswire (US)Eyetech Vision Day to Preview Future of Macugen FranchiseNASDAQ:EYET
14/06/200501:34PR Newswire (US)Eyetech to Host Vision Day on Wednesday, June 22NASDAQ:EYETEyetech Pharmaceuticals (MM)
10/06/200523:29Business WireSchaeffer's Midday Options Update Features General Motors, Citigroup, Northrop Grumman, Intel, and Eyetech PharmaceuticalsNASDAQ:EYETEyetech Pharmaceuticals (MM)
10/06/200514:31PR Newswire (US)Eyetech Announces Appointment of Henry Simon as Chairman of the Board and Resignation of John McLaughlinNASDAQ:EYETEyetech Pharmaceuticals (MM)
09/06/200514:30PR Newswire (US)Eyetech Adopts Stockholder Rights AgreementNASDAQ:EYETEyetech Pharmaceuticals (MM)
25/05/200503:30PR Newswire (US)Eyetech Announces Conference Call to Reiterate Confidence in Macugen(R) (Pegaptanib Sodium Injection)NASDAQ:EYETEyetech Pharmaceuticals (MM)
24/05/200514:30PR Newswire (US)Eyetech Announces Approval of Macugen(R) in Brazil for the Treatment of Neovascular (Wet) Age-Related Macular DegenerationNASDAQ:EYETEyetech Pharmaceuticals (MM)
11/05/200500:30PR Newswire (US)Eyetech to Present at the 2005 UBS Global Pharmaceuticals ConferenceNASDAQ:EYETEyetech Pharmaceuticals (MM)
05/05/200523:10PR Newswire (US)Eyetech Announces Approval of Macugen(R) in Canada for The Treatment of Neovascular (Wet) Age Related Macular DegenerationNASDAQ:EYETEyetech Pharmaceuticals (MM)
05/05/200516:19PR Newswire (US)Macugen(R) (pegaptanib sodium injection) Studied in Treatment of Diabetic Macular Edema (DME) and Other Diabetic Retinopathy LesNASDAQ:EYETEyetech Pharmaceuticals (MM)
02/05/200523:10PR Newswire (US)Preclinical Study Demonstrates Significance of VEGF164 in Pathological NeovascularizationNASDAQ:EYETEyetech Pharmaceuticals (MM)
02/05/200523:10PR Newswire (US)Safety Profile of Macugen(R) (pegaptanib sodium injection) in the Treatment of Neovascular Age-Related Macular Degeneration (AMDNASDAQ:EYETEyetech Pharmaceuticals (MM)
21/04/200523:30PR Newswire (US)Eyetech to Present at Morgan Stanley's Third Annual Global Healthcare Unplugged ConferenceNASDAQ:EYETEyetech Pharmaceuticals (MM)
21/04/200500:09PR Newswire (US)Eyetech Reports First Quarter 2005 Financial ResultsNASDAQ:EYETEyetech Pharmaceuticals (MM)
07/04/200523:30PR Newswire (US)Eyetech Announces Co-Founder Marty Glick Steps Down From Board To Act As ConsultantNASDAQ:EYETEyetech Pharmaceuticals (MM)
07/04/200523:30PR Newswire (US)Eyetech to Announce First Quarter 2005 Financial Results on April 20, 2005NASDAQ:EYETEyetech Pharmaceuticals (MM)
18/03/200522:15PR Newswire (US)Eyetech to Present at the Eighth Annual Lehman Brothers Global Healthcare ConferenceNASDAQ:EYETEyetech Pharmaceuticals (MM)
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EYET

La tua Cronologia

BIT
F17478
Vontobel Financial Produ...
NASDAQ
APWRW
NASDAQ
BREZR
Breeze Holdings Acquisit...
LSE
BC32
Citi Fun 24
ASX
PCC
Probiomics
ASX
MPLBOS
TG
0AJ
Stride
COIN
BSBOTUST
Buoystocks
LSE
HOX
ASX
NEA
Nearmap
COIN
BPLCUST
BlackPearl Token
TSXV
HAO
EU
5609T
5609T
HUOB
JOEUSDT
JoeToken
KRKN
PEPEUSD
Pepe
NASDAQ
OACQU
Origo Acquisition Corporation
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network